Rationale of using hypopigmenting drugs and their clinical application in melasma

Expert Review of Clinical Pharmacology

Volumn 8, Issue 1, 2014, Pages 123-134

  Sardana, Kabir ^a   Ghunawat, Sneha ^a  

^a MAULANA AZAD MEDICAL COLLEGE   (India)

Author keywords

curcumurin; deoxyarbutin; drug; hydroquinone; hypopigmenting; melanogenesis; melasma; methimazole; n butylresorcinol; tyrosinase

Indexed keywords

4 N BUTYLRESORCINOL; ANTIOXIDANT; AZELAIC ACID; DEOXYARBUTIN; DEPIGMENTING AGENT; DIOIC ACID; ELLAGIC ACID; EMBLICA OFFICINALIS EXTRACT; GLUTATHIONE; HESPERIDIN; HEXYLRESORCINOL; HYDROQUINONE; HYPOPIGMENTING DRUG; KOJIC ACID; LICORICE EXTRACT; LINOLEIC ACID ETHYL ESTER; LIQUIRITIN; METFORMIN; NICOTINAMIDE; OXYRESVERATROL; PHENYLALANINE; PLANT EXTRACT; POLYPHENOL; RESVERATROL; RETINOL; SERINE PROTEINASE INHIBITOR; TETRAHEXYLDECYL ASCORBATE; THIAMAZOLE; TRANEXAMIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG; DRUG;

ARTICLE; CHLOASMA; CREAM; DRUG SYNTHESIS; GLYCYRRHIZA; HUMAN; MELANOGENESIS; NONHUMAN; PIGMENTATION; SKIN COLOR; ULTRAVIOLET IRRADIATION; DRUG EFFECTS; MELANOSIS;

HUMANS; MELANOSIS; PHARMACEUTICAL PREPARATIONS; PIGMENTATION;

EID: 84916879347     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2015.977255     Document Type: Article

References (71)

1. Bolognia JL, Pawelek JM. Biology of hypopigmentation. J Am Acad Dermatol 1988;19:217-55
2. Tobin DJ, Bystryn JC. Different populations of melanocytes are present in hair follicles and epidermis. Pigment Cell Res 1996;9:304-10
3. Belleudi F, Purpura V, Scrofani C, et al. Expression and signaling of the tyrosine kinase FGFR2b/KGFR regulates phagocytosis and melanosome uptake in human keratinocytes. FASEB J 2011;25: 170-81
4. Seiberg M, Paine C, Sharlow E, et al. Inhibition of melanosome transfer results in skin lightening. J Invest Dermatol 2000;115:162-7
5. Schiaffino MV. Signaling pathways in melanosome biogenesis and pathology. Int J Biochem Cell Biol 2010;42:1094-104
6. Luger TA, Scholzen T, Grabbe S. The role of alpha melanocyte-stimulating hormone in cutaneous biology. J Invest Dermatol Symp Proc 1997;2:87-93
7. Taieb A, Cario-Andre M, Brigand S, Picardo M. Inhibitors and enhancers of melanogenesis. In: Borovansky J, Patrick A, Riley. Eds Melanins and Melanosomes: Biosynthesis, Biogenesis, physiological, and Pathological Functions. Istedn 2011. 117-54
8. Passeron T. Melasma pathogenesis and influencing factors - an overview of the latest research. J Eur Acad Dermatol Venereol 2013;27(Suppl 1):5-6
9. Gilchrest BA, Park HY, Eller MS, et al. Mechanisms of ultraviolet light-induced pigmentation. Photochem Photobiol 1996;63:1-10
10. Briganti S, Camera E, Picardo M. Chemical and instrumental approaches to treat hyperpigmentation. Pigment Cell Res 2003; 16(2):101-10
11. Solano F, Briganti S, Picardo M, Ghanem G. Hypopigmenting agents: an updated review on biological, chemical and clinical aspects. Pigment Cell Res 2006; 19(6):550-71
12. Zhu W, Gao J. The use of botanical extracts as topical skin-lightening agents for the improvement of skin pigmentation disorders. J Investig Dermatol Symp Proc 2008;13(1):20-4
13. Sato K, Morita M, Ichikawa C, et al. Depigmenting mechanisms of all-trans retinoic acid and retinol on B16 melanoma cells. Biosci Biotechnol Biochem 2008; 72(10):2589-97
14. Baldea I, Costin GE, Shellman Y, et al. Biphasic pro-melanogenic and pro-apoptotic effects of all-trans-retinoic acid (ATRA) on human melanocytes: time-course study. J Dermatol Sci 2013;72(2):168-76
15. Shin JH, Choi GS, Kang WH, Myung KB. Sphingosine 1-phosphate triggers apoptotic signal for B16 melanoma cells via ERK and caspase activation. J Korean Med Sci 2007; 22(2):298-304
16. Lee JE, Kim SY, Jeong YM, et al. The regulatory mechanism of melanogenesis by FTY720, a sphingolipid analogue. Exp Dermatol 2011;20(3):237-41
17. Shin YJ, Han CS, Lee CS, et al. Zeolite 4A, a synthetic silicate, suppresses melanogenesis through the degradation of microphthalmia-associated transcription factor by extracellular signal-regulated kinase activation in B16F10 melanoma cells. Biol Pharm Bull 2010;33(1):72-6
18. Lee J, Jung K, Kim YS, Park D. Diosgenin inhibits melanogenesis through the activation of phosphatidylinositol-3-kinase pathway (PI3K) signaling. Life Sci 2007; 81(3):249-54
19. Lin CB, Babiarz L, Liebel F, et al. Modulation of microphthalmia-associated transcription factor gene expression alters skin pigmentation. J Invest Dermatol 2002; 119(6):1330-40
20. Imokawa G. Analysis of initial melanogenesis including tyrosinase transfer and melanosome differentiation through interrupted melanization by glutathione. J Invest Dermatol 1989;93(1):100-7
21. Ando H, Oka M, Ichihashi M, Mishima Y. Protein kinase C and linoleic acid-induced inhibition of melanogenesis. Pigment Cell Res 1990;3(4):200-6
22. Tu CX, Lin M, Lu SS, et al. Curcumin inhibits melanogenesis in human melanocytes. Phytother Res 2012;26(2): 174-9
23. Jang JY, Lee JH, Jeong SY, et al. Partially purified Curcuma longa inhibits alphamelanocyte- stimulating hormone-stimulated melanogenesis through extracellular signal-regulated kinase or Akt activation-mediated signalling in B16F10 cells. Exp Dermatol 2009;18(8): 689-94
24. Liu WS, Kuan YD, Chiu KH, et al. The extract of Rhodobacter sphaeroides inhibits melanogenesis through the MEK/ERK signaling pathway. Mar Drugs 2013;11(6): 1899-908
25. Boissy RE, Visscher M, DeLong MA. Deoxyarbutin: a novel reversible tyrosinase inhibitor with effective in vivo skin lightening potency. Exp Dermatol 2005;14: 601-8
26. Costa A, Moises TA, Cordero T, et al. Association of emblica, licorice and belides as an alternative to hydroquinone in the clinical treatment of melasma. An Bras Dermatol 2010;85(5):613-20
27. Huh SY, Shin JW, Na JI, et al. The efficacy and safety of 4-n-butylresorcinol 0.1% cream for the treatment of melasma: a randomized controlled split-face trial. Ann Dermatol 2010;22(1):21-5
28. Kolbe L, Mann T, Gerwat W, et al. 4-nbutylresorcinol, a highly effective tyrosinase inhibitor for the topical treatment of hyperpigmentation. J Eur Acad Dermatol Venereol 2013;27(Suppl 1):19-23
29. Shimogaki H, Tanaka Y, Tamai H, Masuda M. In vitro and in vivo evaluation of ellagic acid on melanogenesis inhibition. Int J Cosmetic Sci 2000;22:291-303
30. Kasraee B, Safaee Ardekani GH, Parhizgar A, et al. Safety of topical methimazole for the treatment of melasma. Transdermal absorption, the effect on thyroid function and cutaneous adverse effects. Skin Pharmacol Physiol 2008;21(6): 300-5
31. Malek J, Chedraoui A, Nikolic D, et al. Successful treatment of hydroquinone-resistant melasma using topical methimazole. Dermatol Ther 2013; 26(1):69-72
32. Farshi SJ. Comparative study of therapeutic effects of 20% azelaic acid and hydroquinone 4% cream in the treatment of melasma. Cosmet Dermatol 2011;10(4): 282-7
33. Yu JS, Kim AK. Effect of combination of taurine and azelaic acid on antimelanogenesis in murine melanoma cells. J Biomed Sci 2010;17(Suppl 1):S45
34. Dung TT, Kim SC, Yoo BC, et al. 5- Hydroxy-4-oxo-4H-pyran-2-yl)methyl 6- hydroxynaphthalene-2-carboxylate, a kojic acid derivative, inhibits inflammatory mediator production via the suppression of Syk/Src and NF-kB activation. Int Immunopharmacol 2014;20(1):37-45
35. Seiberg M, Paine C, Sharlow E, et al. The protease-activated receptor 2 regulates pigmentation via keratinocyte-melanocyte interactions. Exp Cell Res 2000;254(1): 25-32
36. Seiberg M. Keratinocyte-melanocyte interactions during melanosome transfer. Pigment Cell Res 2001;14(4):236-42
37. Paine C, Sharlow E, Liebel F, et al. An alternative approach to depigmentation by soybean extracts via inhibition of the PAR-2 pathway. J Invest Dermatol 2001; 116(4):587-95
38. Rivas S, Pandya AG. Treatment of melasma with topical agents, peels and lasers: an evidence-based review. Am J Clin Dermatol 2013;14(5):359-76
39. Fabbrocini G, De Vita V, Marasca C, et al. Salicylic acid for the treatment of melasma: new acquisitions for monitoring the clinical improvement. Skin Res Technol 2013; 19(4):466-73
40. Ni-Komatsu L, Orlow SJ. Identification of novel pigmentation modulators by chemical genetic screening. J Invest Dermatol 2007;127:1585-92
41. Virador VM, Kobayashi N, Matsunaga J, Hearing VJ. A standardized protocol for assessing regulators of pigmentation. Anal Biochem 1999;270:207-19
42. Choi TY, Kim JH, Ko DH, et al. Zebrafish as a new model for phenotype-based screening of melanogenic regulatory compounds. Pigment Cell Res 2007;20: 120-7
43. Su TR, Lin JJ, Tsai CC, et al. Inhibition of melanogenesis by gallic acid: possible involvement of the PI3K/Akt, MEK/ERK and Wnt/b-catenin signaling pathways in B16F10 cells. Int J Mol Sci 2013;14(10): 20443-58
44. Makino ET, Mehta RC, Banga A, et al. Evaluation of a hydroquinone-free skin brightening product using in vitro inhibition of melanogenesis and clinical reduction of ultraviolet-induced hyperpigmentation. J Drugs Dermatol 2013;12(3):s16-20
45. Makino ET, Mehta RC, Garruto J, et al. Clinical efficacy and safety of a multimodality skin brightener composition compared with 4% hydroquinone. J Drugs Dermatol 2013;12(3):s21-6
46. Jones K, Hughes J, Hong M, et al. Modulation of melanogenesis by aloesin: a competitive inhibitor of tyrosinase. Pigment Cell Res 2002;15:335-40
47. Choi S, Lee SK, Kim JE, et al. Aloesin inhibits hyper-pigmentation induced by UV radiation. Clin Exp Dermatol 2002;27: 513-15
48. Jin YH, Lee SJ, Chung MH, et al. Aloesin and arbutin inhibit tyrosinase activity in a synergistic manner via a different action mechanism. Arch Pharm Res 1999;22:232-6
49. Yokota T, Nishio H, Kubota Y, Mizoguchi M. The inhibitory effect of glabridin from licorice extracts on melanogenesis and inflammation. Pigment Cell Res 1998;11(6):355-61
50. Fu B, Li H, Wang X, et al. Isolation and identification of flavonoids in licorice and a study of their inhibitory effects on tyrosinase. J Agric Food Chem 2005;53: 7408-14
51. Amer M, Metwalli M. Topical liquiritin improves melasma. Int J Dermatol 2000;39: 299-301
52. Lee SH, Choi SY, Kim H, et al. Mulberroside F isolated from the leaves of Morus Alba inhibits melanin biosynthesis. Biol Pharm Bull 2002;25:1045-8
53. Handog EB, Galang DA, de Leon-Godinez MA, Chan GP. A randomized, double-blind, placebo-controlled trial of oral procyanidin with vitamins A, C, E for melasma among Filipino women. Int J Dermatol 2009; 48(8):896-901
54. Khemis A, Kaiafa A, Queille-Roussel C, et al. Evaluation of efficacy and safety of rucinol serum in patients with melasma: a randomized controlled trial. Br J Dermatol 2007;156(5):997-1004
55. Katoulis A, Alevizou A, Soura E, et al. A double-blind vehicle-controlled study of a preparation containing undecylenoyl phenylalanine 2% in the treatment of melasma in females. J Cosmet Dermatol 2014;13(2):86-90
56. Keeling J, Cardona L, Benitez A, et al. Mequinol 2%/tretinoin 0.01% topical solution for the treatment of melasma in men: a case series and review of the literature. Cutis 2008;81(2):179-8
57. Kakita LS, Lowe NJ. Azelaic acid and glycolic acid combination therapy for facial hyperpigmentation in darker-skinned patients: a clinical comparison with hydroquinone. Clin Ther 1998;20(5): 960-70
58. Malek J, Chedraoui A, Nikolic D, et al. Successful treatment of hydroquinone-resistant melasma using topical methimazole. Dermatol Ther 2013; 26(1):69-72
59. Monteiro RC, Kishore BN, Bhat RM, et al. A comparative study of the efficacy of 4% hydroquinone vs 0.75% kojic acid cream in the treatment of facial melasma. Indian J Dermatol 2013;58(2):157
60. Verallo-Rowell VM, Verallo V, Graupe K, Lopez-Villafuerte L. Double-blind comparison of azelaic acid and hydroquinone in the treatment of melasma. Acta Derm Venereol Suppl (Stockh) 1989;143:58-61
61. Iraji F, Tagmirriahi N, Gavidnia K. Comparison between the efficacy of 10% zinc sulfate solution with 4% hydroquinone cream on improvement of melasma. Adv Biomed Res 2012;1:39
62. Li Y, Sun Q, He Z, et al. Treatment of melasma with oral administration of compound tranexamic acid: a preliminary clinical trial. J Eur Acad Dermatol Venereol 2014;28(3):393-4
63. Tse TW, Hui E. Tranexamic acid: an important adjuvant in the treatment of melasma. J Cosmet Dermatol 2013;12(1): 57-66
64. Funasaka Y, Komoto M, Ichihashi M. Depigmenting effect of alpha-tocopheryl ferulate on normal human melanocytes. Pigment Cell Res 2000;13(Suppl 8):170-4
65. Lehraiki A, Abbe P, Cerezo M, et al. Inhibition of melanogenesis by the antidiabetic metformin. J Invest Dermatol 2014;134(10):2589-97
66. Sardana K, Chugh S, Garg VK. Which therapy works for melasma in pigmented skin: lasers, peels, or triple combination creams? Indian J Dermatol Venereol Leprol 2013;79(3):420-2
67. Sardana K, Garg VK. Lasers are not effective for melasma in darkly pigmented skin. J Cutan Aesthet Surg 2014;7(1): 57-60
68. Hakozaki T, Minwalla L, Zhuang J, et al. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol 2002; 147(1):20-31
69. Tirado-Sánchez A, Santamaría-Román A, Ponce-Olivera RM. Efficacy of dioic acid compared with hydroquinone in the treatment of melasma. Int J Dermatol 2009; 48(8):893-5
70. Shoji T, Masumoto S, Moriichi N, et al. Procyanidin trimers to pentamers fractionated from apple inhibit melanogenesis in B16 mouse melanoma cells. J Agric Food Chem 2005;53:6105-11
71. Lu Y, Zhu WY, Tan C. Effects of sophocarpidine and cinnamic acid on the melanogenesis of melan-a. J Clin Dermatol 2006;35:698-700